Lymph Nodes News and Research RSS Feed - Lymph Nodes News and Research

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Novogen Limited, Australian/US biotechnology company, today announces that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in pre-clinical studies also to be highly active against melanoma. [More]
Targeted therapy with radiopharmaceuticals has great potential for cancer treatment

Targeted therapy with radiopharmaceuticals has great potential for cancer treatment

Cancer therapy can be much more effective using a new way to customize nuclear medicine treatment, researchers say in the December 2014 issue of The Journal of Nuclear Medicine. The process could also be useful for other diseases that could benefit from targeted radiation. [More]
Study: Injectable 3D vaccines could help prevent cancer, infectious disease

Study: Injectable 3D vaccines could help prevent cancer, infectious disease

One of the reasons cancer is so deadly is that it can evade attack from the body's immune system, which allows tumors to flourish and spread. Scientists can try to induce the immune system, known as immunotherapy, to go into attack mode to fight cancer and to build long lasting immune resistance to cancer cells. [More]
AbbVie reports results from venetoclax Phase 2 clinical trial in AML at ASH 2014

AbbVie reports results from venetoclax Phase 2 clinical trial in AML at ASH 2014

AbbVie presented during an oral presentation at the American Society of Hematology's 56th Annual Meeting new results from a Phase 2 study of investigational compound venetoclax (ABT-199/GDC-0199) in patients with acute myelogenous leukemia (AML). AML is an aggressive and deadly type of blood cancer, in which the body produces too many of a specific type of white blood cell (myeloblast), which can crowd out healthy blood cells. [More]
Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

Merck, known as MSD outside of Canada and the United States, announced today early study findings demonstrating that patients treated with pembrolizumab, the company's investigational anti-PD-1 cancer therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19/29: 95% CI, 46-82). [More]
Endomagnetics gets FDA's IDE approval to begin clinical trial of SentiMag and Sienna+ system

Endomagnetics gets FDA's IDE approval to begin clinical trial of SentiMag and Sienna+ system

Cancer healthcare company Endomagnetics announced today that it has received Investigational Device Exemption (IDE) approval from the United States Food and Drug Administration to initiate a pivotal clinical trial to evaluate the safety and effectiveness of the SentiMag and Sienna+ magnetic sentinel lymph node biopsy system in the management of breast cancer. [More]
Gastric cancer patients who receive chemoradiation after surgery have better survival rates

Gastric cancer patients who receive chemoradiation after surgery have better survival rates

Patients who receive chemotherapy and radiation after surgery for gastric cancer appear to have better survival rates than those who had surgery followed by only chemotherapy, according to results of a look-back study of more than 500 people by Johns Hopkins scientists. [More]
Study finds significant disparities in lung cancer treatment based on race, insurance status

Study finds significant disparities in lung cancer treatment based on race, insurance status

African Americans, Hispanics, and those who receive care at a community hospital are all significantly less likely than other patients to receive treatment for early stage non-small cell lung cancer, according to a report in the Journal of Thoracic Oncology. [More]
Researchers use cutting-edge software to predict aggressive breast cancer tumours

Researchers use cutting-edge software to predict aggressive breast cancer tumours

Researchers at Western University are using cutting-edge genetic mutation-analysis software developed in their lab to interpret mutations in tumour genome that may provide insight into determining which breast cancer tumours are more likely spread to other parts of the body and which ones won't. [More]
Breakthrough study shows novel molecular imaging drug to detect early prostate cancer

Breakthrough study shows novel molecular imaging drug to detect early prostate cancer

A novel study demonstrates the potential of a novel molecular imaging drug to detect and visualize early prostate cancer in soft tissue, lymph nodes and bone. The research, published in the November issue of the Journal of Nuclear Medicine, compares the biodistribution and tumor uptake kinetics of two Tc-99m labeled ligands, MIP-1404 and MIP-1405, used with SPECT and planar imaging. [More]
Incidence of colon and rectal cancer expected to increase by 2030 among young patients

Incidence of colon and rectal cancer expected to increase by 2030 among young patients

In the next 15 years, more than one in 10 colon cancers and nearly one in four rectal cancers will be diagnosed in patients younger than the traditional screening age, according to researchers at The University of Texas MD Anderson Cancer Center. [More]
UT Arlington professor uses tissue-engineered artificial lymph nodes to draw prostate cancer cells

UT Arlington professor uses tissue-engineered artificial lymph nodes to draw prostate cancer cells

A UT Arlington bioengineering professor is using tissue-engineered artificial lymph nodes to attract prostate cancer cells to better target and eradicate the disease. [More]
New studies offer hope for breast cancer survivors struggling with cancer-related pain, swelling

New studies offer hope for breast cancer survivors struggling with cancer-related pain, swelling

Two new studies from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania offer hope for breast cancer survivors struggling with cancer-related pain and swelling, and point to ways to enhance muscular strength and body image. [More]
Study reports IL-37's activity in the adaptive immune system

Study reports IL-37's activity in the adaptive immune system

A University of Colorado Cancer Center study published in this month's Proceedings of the National Academy of Sciences describes the activity of a recently discovered communication molecule of the body's immune system, Interleukin 37 or IL-37. It has been known to limit inflammation and the current study reports its activity in the adaptive immune system: IL-37 inhibits the ability of the immune system to recognize and target new antigens. [More]
CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended September 30, 2014, and also provided an overview of recent accomplishments by and upcoming milestones for its clinical development programs. [More]
New research sheds light on future efforts to eradicate HIV from the body in human patients

New research sheds light on future efforts to eradicate HIV from the body in human patients

Where does HIV hide? Antiretroviral drugs can usually control the virus, but can't completely eliminate it. So any strategy to eradicate HIV from the body has to take into account not only the main group of immune cells the virus targets, called CD4 or helper T cells, but other infected cells as well. [More]
PORT can improve survival for non-small cell lung cancer patients

PORT can improve survival for non-small cell lung cancer patients

Patients who received post-operative radiation therapy (PORT), radiation therapy after surgery, lived an average of four months longer when compared to the patients who had the same disease site, tumor histology and treatment criteria and who did not receive PORT, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology. [More]
Rutgers scientists are developing new medical imaging method for early detection of cancer

Rutgers scientists are developing new medical imaging method for early detection of cancer

A new medical imaging method being developed at Rutgers University could help physicians detect cancer and other diseases earlier than before, speeding treatment and reducing the need for invasive, time-consuming biopsies. [More]
Study reveals that people with stress-related inflammation may suffer from depression

Study reveals that people with stress-related inflammation may suffer from depression

Preexisting differences in the sensitivity of a key part of each individual's immune system to stress confer a greater risk of developing stress-related depression or anxiety, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published October 20 in the Proceedings of the National Academy of Sciences. [More]
Biomarker test available for breast cancer, but remains unclear for patients with intermediate risk of recurrence

Biomarker test available for breast cancer, but remains unclear for patients with intermediate risk of recurrence

To make a decision for or against adjuvant chemotherapy, a test to measure the concentrations of the biomarkers uPA and PAI-1 in the tumour tissue is available for breast cancer patients. [More]